At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 18 enrolled
Drug / intervention
Ramucirumab +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1b Study of Ramucirumab in Combination With Fluoropyrimidines and Platinum-Based Agents in Japanese Patients With Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
In Brief
A Phase 1 clinical trial evaluating Ramucirumab, Capecitabine, and 3 other interventions for Stomach Neoplasms. Completed, enrolled 18 participants across 4 sites.
Detailed Summary
The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and antitumor response of ramucirumab in combination with platinum/fluoropyrimidine regimens in Japanese participants with advanced gastric/gastrooesophageal junction cancer who have not received chemotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStomach Neoplasms
CountriesJapan
Collaborators--
Timeline
Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartFeb 2015
First PostedFeb 2015
Primary CompletionJul 2016
Study CompletionNov 2016
TodayJul 2026
First PostedFeb 9, 2015
Enrollment StartFeb 1, 2015
Primary CompletionJul 1, 2016
Study CompletionNov 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 11.4 years ago
Interventions
Ramucirumabdrug
Administered IV
Capecitabinedrug
Administered orally
Cisplatindrug
Administered IV
S-1drug
Administered orally
Oxaliplatindrug
Administered IV